Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Total Liabilities (2016 - 2025)

Historic Total Liabilities for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $760.9 million.

  • United Therapeutics' Total Liabilities fell 2556.25% to $760.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $760.9 million, marking a year-over-year decrease of 2556.25%. This contributed to the annual value of $920.0 million for FY2024, which is 2217.9% down from last year.
  • As of Q3 2025, United Therapeutics' Total Liabilities stood at $760.9 million, which was down 2556.25% from $734.4 million recorded in Q2 2025.
  • United Therapeutics' 5-year Total Liabilities high stood at $1.3 billion for Q3 2023, and its period low was $734.4 million during Q2 2025.
  • Moreover, its 5-year median value for Total Liabilities was $1.2 billion (2021), whereas its average is $1.1 billion.
  • Per our database at Business Quant, United Therapeutics' Total Liabilities surged by 1097.09% in 2021 and then tumbled by 2842.11% in 2025.
  • United Therapeutics' Total Liabilities (Quarter) stood at $1.2 billion in 2021, then rose by 3.11% to $1.2 billion in 2022, then fell by 5.26% to $1.2 billion in 2023, then decreased by 22.18% to $920.0 million in 2024, then fell by 17.29% to $760.9 million in 2025.
  • Its Total Liabilities was $760.9 million in Q3 2025, compared to $734.4 million in Q2 2025 and $936.7 million in Q1 2025.